FDA Renews Blood Products Advisory Committee Charter Through 2028

The Food and Drug Administration announced the renewal of the Blood Products Advisory Committee (BPAC) in a Federal Register notice scheduled for publication tomorrow. The renewal authorizes the committee to operate through May 13, 2028.

The BPAC is a discretionary federal advisory committee established to provide advice to the commissioner of food and drugs. The BPAC reviews and evaluates available data concerning the safety, effectiveness and appropriate use of blood, products derived from blood and serum or biotechnology that are intended for use in the diagnosis, prevention or treatment of human diseases. 

In the notice, FDA highlighted BPAC’s role in informing the agency’s January 2025 draft guidance on strategies to reduce transfusion-transmitted malaria risk. The agency cited discussions held during the committee’s May 2024 meeting on malaria testing approaches for at-risk donors and donations.